Keynote | Why Do We Need New Lipid Lowering Therapies?

Disclosure(s):

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)